We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Review |

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure A Systematic Review and Pooled Analysis

Jonathan Z. Li, MD; Roger Paredes, MD, PhD; Heather J. Ribaudo, PhD; Evguenia S. Svarovskaia, PhD; Karin J. Metzner, MD; Michael J. Kozal, MD; Kathy Huppler Hullsiek, PhD; Melanie Balduin, PhD; Martin R. Jakobsen, PhD, Msc; Anna Maria Geretti, MD, PhD; Rodolphe Thiebaut, MD, PhD; Lars Ostergaard, MD, PhD; Bernard Masquelier, PharmD, PhD; Jeffrey A. Johnson, PhD; Michael D. Miller, PhD; Daniel R. Kuritzkes, MD
JAMA. 2011;305(13):1327-1335. doi:10.1001/jama.2011.375.
Text Size: A A A
Published online

Context Presence of low-frequency, or minority, human immunodeficiency virus type 1 (HIV-1) drug resistance mutations may adversely affect response to antiretroviral treatment (ART), but evidence regarding the effects of such mutations on the effectiveness of first-line ART is conflicting.

Objective To evaluate the association of preexisting drug-resistant HIV-1 minority variants with risk of first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)–based antiretroviral virologic failure.

Data Sources Systematic review of published and unpublished studies in PubMed (1966 through December 2010), EMBASE (1974 through December 2010), conference abstracts, and article references. Authors of all studies were contacted for detailed laboratory, ART, and adherence data.

Study Selection and Data Abstraction Studies involving ART-naive participants initiating NNRTI-based regimens were included. Participants were included if all drugs in their ART regimen were fully active by standard HIV drug resistance testing. Cox proportional hazard models using pooled patient-level data were used to estimate the risk of virologic failure based on a Prentice weighted case-cohort analysis stratified by study.

Data Synthesis Individual data from 10 studies and 985 participants were available for the primary analysis. Low-frequency drug resistance mutations were detected in 187 participants, including 117 of 808 patients in the cohort studies. Low-frequency HIV-1 drug resistance mutations were associated with an increased risk of virologic failure (hazard ratio (HR], 2.3 [95% confidence interval {CI}, 1.7-3.3]; P < .001) after controlling for medication adherence, race/ethnicity, baseline CD4 cell count, and plasma HIV-1 RNA levels. Increased risk of virologic failure was most strongly associated with minority variants resistant to NNRTIs (HR, 2.6 [95% CI, 1.9-3.5]; P < .001). Among participants from the cohort studies, 35% of those with detectable minority variants experienced virologic failure compared with 15% of those without minority variants. The presence of minority variants was associated with 2.5 to 3 times the risk of virologic failure at either 95% or greater or less than 95% overall medication adherence. A dose-dependent increased risk of virologic failure was found in participants with a higher proportion or quantity of drug-resistant variants.

Conclusion In a pooled analysis, low-frequency HIV-1 drug resistance mutations, particularly involving NNRTI resistance, were significantly associated with a dose-dependent increased risk of virologic failure with first-line ART.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1. Study Selection
Graphic Jump Location

NNRTI indicates nonnucleoside reverse transcriptase inhibitor.
aInternational HIV Drug Resistance Workshop and Conference on Retroviruses and Opportunistic Infections (2007-2010).
bCommon reasons for exclusion include: does not involve low-frequency resistance variants, review article, epidemiologic study, and treatment-experienced population only.

Place holder to copy figure label and caption
Figure 2. Kaplan-Meier Curves for Proportion of Patients Without Virologic Failure by Presence of Drug-Resistant HIV-1 Minority Variants
Graphic Jump Location

Both nonnucleoside reverse transcriptase inhibitor–and nucleoside reverse transcriptase inhibitor–resistant minority variants (MVs) are included in this analysis. To avoid bias induced by targeted sampling in case-control studies, Kaplan-Meier failure time distributions were estimated using only data from cohort studies.1521 Curves only shown to 1250 days because of small sample sizes thereafter. P value comparison by Cox proportional hazard analysis. Median follow-up time, 31 (interquartile range, 13-34) months. HIV indicates human immunodeficiency virus.

Place holder to copy figure label and caption
Figure 3. Effect of Minority Variants and Antiretroviral Therapy Adherence on Virologic Failure
Graphic Jump Location

NNRTI indicates nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
aParticipant numbers include additional virologic failure cases from the case-control and case-cohort studies.2124
bCox proportional hazard ratios shown are in comparison to those without minority variants unless otherwise noted.
c Three studies contributed to the adherence analysis.15,20,21 One study was excluded from the minority variant 1% threshold analysis because of a limit of detection of 2% for the assay,18 and only NNRTI-resistant minority variants were evaluated for 2 studies because of incompatible limits of detection for NRTI-resistant minority variants.22,23 Four studies were excluded from the 0.5% threshold analysis because of higher limits of minority variant detection.15,18,22,23 Analysis of minority variant copy numbers excluded 3 studies using assays that could not provide a percentage.18,22,23
dMultivariate Cox regression analysis included adherence, race/ethnicity, baseline CD4 cell count, and HIV-1 RNA levels.

Place holder to copy figure label and caption
Figure 4. Time to HIV-1 RNA Level Less Than 200 Copies/mL in Patients Achieving Virologic Suppression
Graphic Jump Location

Two studies with frequent human immunodeficiency virus 1 (HIV-1) RNA monitoring20,21 were used to determine the time to HIV-1 RNA less than 200 copies/mL among individuals who experienced virologic suppression. P value comparison by Cox proportional hazard analysis. Median time to virologic suppression was 57 (interquartile range, 28-112) days for those with minority variants and 57 (interquartile range, 27-111) days for those without.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles